ArisGlobal spent much of the last decade helping life sciences companies modernize their Safety and Regulatory systems. In 2025, the company crossed a more consequential threshold: AI stopped being an experiment and became operational infrastructure.
The AI-first life sciences technology firm behind the LifeSphere® platform reported a year of strong customer growth, large-scale global implementations, and accelerating adoption of its NavaX AI capabilities. More telling than raw numbers, however, is where those deployments landed—not in labs or innovation sandboxes, but in live, regulated, enterprise production environments.
That shift matters. For an industry defined by regulatory scrutiny, massive data volumes, and zero tolerance for error, “AI in production” isn’t a buzz phrase. It’s a signal that trust, governance, and measurable outcomes are finally catching up to ambition.
AI Moves From Pilot Projects to Core Systems
Life sciences companies have spent years testing AI in limited pilots, often constrained to narrow use cases or isolated data sets. In 2025, ArisGlobal saw that dynamic change decisively.
The company added or expanded relationships with more than 100 customers across LifeSphere during the year. Adoption of NavaX—the AI layer embedded across Safety and Regulatory workflows—grew 125% year over year, driven largely by enterprise-scale deployments rather than departmental trials.
That pattern reflects a broader industry reality. Regulatory pressure is increasing, submission timelines are tightening, and data volumes from clinical, post-market, and real-world sources continue to explode. Manual processes and legacy systems are no longer sustainable, and incremental automation isn’t enough.
“Customers are no longer experimenting with AI—they’re operationalizing it,” said Steve Nuckols, ArisGlobal’s Chief Customer Officer. The results organizations are prioritizing—cycle time reduction, consistency, and inspection readiness—are pragmatic, not aspirational.
Scaling Global Implementations Without Breaking Compliance
One of the hardest problems in life sciences IT isn’t innovation; it’s execution at scale. Global rollouts across regions, business units, and regulatory regimes are notoriously complex, especially when AI is involved.
In 2025, ArisGlobal completed 38 global go-lives:
- 22 Safety implementations
- 11 Regulatory implementations
- 5 NavaX AI go-lives
Among them were deployments for three of the world’s top 10 pharmaceutical companies, including some of the industry’s earliest production implementations of advanced AI capabilities in regulated workflows.
That’s notable because AI systems in Safety and Regulatory environments must meet far higher standards than typical enterprise software. Validation, auditability, explainability, and data lineage aren’t optional—they’re table stakes.
According to COO Raj Hattarki, speed and compliance don’t have to be trade-offs. “These were complex, global programs, yet we helped customers go live faster without compromising compliance or long-term foundations,” he said, emphasizing that accelerating time to value is critical when every delayed day represents lost operational impact.
From AI Features to Intelligent Orchestration
If 2024 was about adding AI features, 2025 was about re-architecting how intelligence flows across the enterprise.
ArisGlobal’s product strategy evolved LifeSphere from a collection of functional systems into a more connected, intelligence-driven operating model. Instead of isolated automation, the company focused on orchestration—connecting data, workflows, and decisions across domains.
Three major launches defined that shift:
Unify
Unify acts as a data orchestration layer spanning Safety, Regulatory, Quality, and Medical data. Rather than forcing organizations to reconcile information across silos, it provides a shared foundation for cross-domain visibility, reporting, and decision-making. For global pharma companies, this kind of unification directly impacts inspection readiness and executive oversight.
NavaX Insights
NavaX Insights moves beyond task automation into real-time intelligence. It analyzes operational and safety data to surface trends, monitor performance, and flag risks as they emerge. This turns Safety and Regulatory systems from reactive repositories into proactive management tools.
NavaX Agents
Perhaps the most forward-looking addition, NavaX Agents introduce agentic AI into Safety and Regulatory workflows. Instead of executing predefined rules, these agents can assist with analysis, prioritization, and workflow progression—under human oversight—marking a step toward more adaptive enterprise AI.
Today, NavaX collectively processes around 700,000 cases annually. ArisGlobal expects that figure to grow to 2.5 million cases by mid-2026, a scale that underscores how deeply AI is becoming embedded in daily operations.
Trust, Governance, and Recognition
Enterprise AI adoption in life sciences hinges on trust—both from regulators and from internal teams accountable for compliance. ArisGlobal has leaned heavily into that reality.
In 2025, the company received the Frost & Sullivan New Product Innovation Award, recognizing its progress in AI-driven life sciences platforms. It also continued active participation in the EU AI Pact, reinforcing its emphasis on responsible AI design in highly regulated environments.
“AI stopped being theoretical and started delivering results,” said Ann-Marie Orange, CIO and Global Head of R&D. The shift, she noted, isn’t just about automation—it’s about orchestrating data and decisions across the enterprise in ways that were previously impractical.
A Clear Signal for the Life Sciences Market
ArisGlobal’s 2025 results reflect a larger inflection point for the industry. Life sciences organizations are no longer asking whether AI can work in regulated environments. They’re asking how fast it can scale, how reliably it can operate, and how directly it can improve outcomes.
By focusing on orchestration, validation, and enterprise deployment—rather than flashy but fragile innovation—ArisGlobal is positioning itself as a long-term infrastructure provider, not just a technology vendor.
That distinction matters as AI enters what many executives now call its “enterprise phase,” where value is measured less by novelty and more by durability.
Looking Ahead to 2026
Heading into 2026, ArisGlobal says its priorities are clear: scale enterprise AI adoption, deepen its role as a data intelligence partner, and continue building systems designed for real-world operations—not demos.
CEO Aman Wasan summed up the approach succinctly: “This year proved what’s possible when AI is deployed responsibly and designed for real-world operations.” The focus, he said, will remain on intelligent orchestration, trust by design, and outcomes that matter for patients, regulators, and the teams supporting them.
For an industry that rarely moves fast without proof, 2025 may be remembered as the year AI finally earned its place in the life sciences production stack.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
